z-logo
open-access-imgOpen Access
Large-scale Artemisinin–Piperaquine Mass Drug Administration With or Without Primaquine Dramatically Reduces Malaria in a Highly Endemic Region of Africa
Author(s) -
Changsheng Deng,
Bo Huang,
Qi Wang,
Wanting Wu,
Shaoqin Zheng,
Hongying Zhang,
Di Li,
Danghong Feng,
Guoming Li,
Linlu Xue,
Tao Yang,
Fei Tuo,
Fouad Mohadji,
Xinzhuan Su,
Qin Xu,
Zhibing Wu,
Lin Li,
Jiuyao Zhou,
Hong Yan,
Affane Bacar,
Kamal Said Abdallah,
Rachadi A Kéké,
Ahamada M. S. A. Mliva,
Moussa Mohamed,
Xinhua Wang,
Shiguang Huang,
Fatihou Oithik,
Xiaobo Li,
Fangli Lü,
Michael P. Fay,
Xiaohong Liu,
Thomas E. Wellems,
Jianping Song
Publication year - 2018
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciy364
Subject(s) - primaquine , malaria , artemisinin , piperaquine , plasmodium falciparum , population , medicine , mass drug administration , adverse effect , immunology , chloroquine , environmental health
Mass drug administration (MDA), with or without low-dose primaquine (PMQLD), is being considered for malaria elimination programs. The potential of PMQLD to block malaria transmission by mosquitoes must be balanced against liabilities of its use.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom